On March 7, biopharmaceutical company LENZ Therapeutics announced that it raised $83.5 million in an oversubscribed Series B financing. The financing was led by new investor Sectoral Asset Management alongside Alpha Wave Ventures and Point 72. Existing investors RA Capital Management, Versant Ventures, RTW Investments, and others also participated. Wilson Sonsini Goodrich & Rosati represented LENZ in the transaction.

LENZ has late clinical-stage programs LNZ100 (aceclidine) and LNZ101 (aceclidine and brimonidine), which offer potential best-in-class therapies for presbyopia, or age-related far sightedness.  The proceeds from the financing will allow LENZ to complete the development and registration and, pending approval, launch LNZ100/101 in the United States. LENZ also announced the initiation of a Phase 3 CLARITY program in December 2022.

For more information, please see the Lenz press release. The Wilson Sonsini team includes:

Corporate
Dan Koeppen
Ben Capps
Bridget Balisy

Intellectual Property
Mike Hostetler
Greg Mitchell
Tyler Bird

Technology Transactions - Biotech
Ian Edvalson
Shefali Tandon